PEL

PIRAMAL ENTERPRISES

Large Cap BSE: 500302 NSE: PEL
₹864.25
21 (2.49%)
As on 02 October, 2022 | 17:35

Piramal Enterprises Share Price

Piramal Enterprises Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in PIRAMAL ENTERPRISES

Start SIP

Piramal Enterprises Share Returns

  • Over 1 Month -18.74%
  • Over 3 Month -47.8%
  • Over 6 Month -61.3%
  • Over 1 Year -66.71%

Piramal Enterprises Key Statistics

P/E Ratio 11
PEG Ratio 0.3
Market Cap Cr 20,627
Price to Book Ratio 0.6
EPS 22.9
Dividend 3.8
Relative Strength Index 22.93
Money Flow Index 24.95
MACD Signal -180.77
Average True Range 54.46

Piramal Enterprises Investment Rating

  • Master Rating:
  • Piramal Enterprises has an operating revenue of Rs. 14,632.99 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 13% is healthy, ROE of 5% is fair but needs improvement. The company has a high debt to equity of 123%, which can be a reason to worry. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 39 which is a POOR score indicating inconsistency in earnings, a RS Rating of 6 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 127 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Piramal Enterprises Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 513574624515513494
Operating Expenses Qtr Cr 357341297318301199
Operating Profit Qtr Cr 151232327197211295
Depreciation Qtr Cr 666657
Interest Qtr Cr 156168207203183181
Tax Qtr Cr 44424-5651
Net Profit Qtr Cr 28316169345379

Piramal Enterprises Technicals

EMA & SMA

Current Price
864.25
21 (2.49%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 1028.22
  • 50 Day
  • 1308.12
  • 100 Day
  • 1560.84
  • 200 Day
  • 1955.55
  • 20 Day
  • 959.66
  • 50 Day
  • 1447.54
  • 100 Day
  • 1594.63
  • 200 Day
  • 1957.11

Piramal Enterprises Resistance and Support

PIVOT
₹848.14
Resistance
First Resistance 865.12
Second Resistance 886.99
Third Resistance 903.97
RSI 22.93
MFI 24.95
MACD Single Line -180.77
MACD -166.02
Support
First Resistance 826.27
Second Resistance 809.29
Third Resistance 787.42

Piramal Enterprises Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 994,132 32,935,593 33.13
Week 1,470,037 40,911,141 27.83
1 Month 1,495,995 48,754,490 32.59
6 Month 1,195,732 42,520,229 35.56

Piramal Enterprises Result Highlights

Piramal Enterprises Synopsis

NSE-Medical-Diversified

Piramal Enterprises is involved in the business activities of Other financial service activities, except insurance and pension funding activities. Company’s Total Operating Revenue is Rs. 2225.68 Cr. and Equity Capital is Rs. 47.73 Cr. for the Year ended 31/03/2022. Piramal Enterprises Ltd. is a Public Limited Listed company incorporated on 26/04/1947 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24110MH1947PLC005719 and registration number is 005719.
Market Cap 20,627
Sales 2,226
Shares in Float 13.60
No of funds 624
Yield 3.82
Book Value 0.89
U/D Vol ratio 1
LTDebt / Equity 16
Alpha -0.19
Beta 1.42

Piramal Enterprises

Owner NameJun-22Mar-22Dec-21
Promoters 43.49%43.49%43.49%
Mutual Funds 2.02%2.18%1.56%
Insurance Companies 6.03%6.18%6.57%
Foreign Portfolio Investors 34.54%35.03%35.31%
Financial Institutions/ Banks
Individual Investors 9.29%8.93%8.68%
Others 4.63%4.19%4.39%

Piramal Enterprises Management

Name Designation
Mr. Ajay G Piramal Chairman
Dr.(Mrs.) Swati A Piramal Vice Chairperson
Ms. Nandini Piramal Executive Director
Mr. Puneet Dalmia Independent Director
Mr. Anand Piramal Non Executive Director
Mr. Vijay Shah Non Executive Director
Mr. Kunal Bahl Independent Director
Mr. Khushru Jijina Executive Director
Ms. Anjali Bansal Independent Director
Mr. S Ramadorai Independent Director
Mr. Shikha Sharma Independent Director
Mr. N Vaghul Independent Director
Mr. Suhail Nathani Independent Director
Mr. Anita George Independent Director
Mr. Rajiv Mehrishi Independent Director

Piramal Enterprises Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Piramal Enterprises Corporate Action

Date Purpose Remarks
2022-07-29 Quarterly Results
2022-07-14 To consider raising of funds
2022-05-26 Audited Results & Final Dividend
2022-02-10 Quarterly Results
2021-11-11 Quarterly Results
Date Purpose Remarks
2022-07-15 FINAL Rs.33.00 per share(1650%)Final Dividend
2021-07-07 FINAL Rs.33.00 per share(1650%)Final Dividend

Piramal Enterprises MF Shareholding

Name Amount(cr)
Kotak Equity Arbitrage Fund Growth 23310
Kotak Balanced Advantage Fund Regular Growth 14587
ICICI Prudential Equity Arbitrage Fund Regular Growth 11507
Nippon India Arbitrage Fund Growth 9331
Edelweiss Balanced Advantage Fund Regular Plan Growth 8733

About Company

Piramal Enterprises Limited is an Indian multinational pharmaceutical and financial services company based in Mumbai, Maharashtra. Founded by Ajay Piramal (who is also the Chairman), the company operates in the pharmaceuticals, financial services and real estate sector.

He founded the company in 1984 after he acquired a small-scale manufacturing unit from his father. Today, Piramal has more than 50 offices across 30 countries and employs over 10,000 people worldwide. With a presence in 100+ countries through its subsidiaries or associate companies. Piramal has been ranked among Forbes Asia’s 200 Best Under A Billion in 2019.

Business Verticals

PEL's Global Pharma division has a strong product portfolio of niche differentiated branded generics that are difficult to manufacture, sell, or distribute. Through its worldwide network of facilities, PEL's Contract Development and Manufacturing Organisation (CDMO) services segment provide end-to-end solutions across the drug life cycle. 

The Indian consumer products division of PEL serves India’s self-care market. PEL's OTC portfolio includes 21 major pharmaceutical and personal care brands in diverse product categories such as Vitamins & Nutrition, Dermatological & Antacids, Analgesics, and Baby Care. PEL's Healthcare Insights & Analytics division is the world's leading provider of healthcare analytics data, insight products and services to the world's leading pharma, biotech and medical technology companies, allowing them to make informed business decisions.

PEL's financial services include wholesale lending, housing finance, and alternative asset management. Piramal Capital & Housing Finance Ltd, PEL's wholly-owned subsidiary, is registered as a housing finance company with National Housing Bank (NHB) and is involved in a variety of financial services businesses. It offers wholesale and retail funding opportunities across industries.

Company History

Piramal Enterprises was founded as Indian Schering Limited on April 26, 1947, by British Schering Ltd. With effect from September 27, 1979, the company's name was changed from Indian Schering Ltd to Nicholas Laboratories India Ltd. Gujarat Glass Ltd (GGL) was acquired with the company on April 1, 1990. The new formulation plant in Pithampur, Madhya Pradesh, was inaugurated in 1991. After a year, in 1992, the company established a second formulation plant in Pithampur, Madhya Pradesh, with cutting-edge manufacturing facilities. The company's name changed from 'Nicholas Laboratories Ltd' to 'Nicholas Piramal India Ltd' on December 2, 1992.
 

Milestones

1988
Entered the pharmaceutical industry with the purchase of Nicholas Laboratories.
A series of mergers and acquisitions, joint ventures and alliances, and organic initiatives.

2010
Over two decades, they built a leading Indian pharmaceutical company.
The Domestic Formulations business was sold to Abbott in 2010 for USD 3.8 billion. Diagnostic Services were sold to Super Religare Laboratories.

From 2020 onwards
Multiple capital raise initiatives helped to strengthen the balance sheet.
Through the sale of DRG and the exit of Shriram Transport, the organization structure was simplified.
Subsidized the pharmaceutical businesses and raised new capital from Carlyle Transforming Financial Services with the DHFL acquisition to deliver long-term growth and profitability.
 

Piramal Enterprises FAQs

What is Share Price of Piramal Enterprises ?

Piramal Enterprises share price is ₹864 As on 02 October, 2022 | 17:21

What is the Market Cap of Piramal Enterprises ?

The Market Cap of Piramal Enterprises is ₹20626.5 Cr As on 02 October, 2022 | 17:21

What is the P/E ratio of Piramal Enterprises ?

The P/E ratio of Piramal Enterprises is 11 As on 02 October, 2022 | 17:21

What is the PB ratio of Piramal Enterprises ?

The PB ratio of Piramal Enterprises is 0.6 As on 02 October, 2022 | 17:21

What were the company's most recent reported sales and net income?

Piramal Enterprises Ltd recorded net sales of INR 13993 crores in the year ending March 2022. 

What is the future of the company's shares?

Piramal Enterprises Ltd stock may be a good buy according to market analysts considering meaningful inroads into Retail led by mortgages and small-term loans via digital alliance.

How to buy shares of Piramal Enterprises Ltd.?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

Q1FY23